Skip to main content

Table 5 Overall survival (OS) and progression-free survival (PFS) of the studied cases

From: Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups

  Mean (months) 95% CI Median (months) % 1 year % 2 year (end of study)
Overall survival (OS) 19.1 17.1-21.1 24 77.5% 50%
Progression-free survival (PFS) 15.83 13.6-18.1 17 65% 27.5%
  1. CI confidence interval